News

Sydney, Australia-The introduction of the Perfect Pupil Injector (Becton, Dickinson and Co. [BD]) has made implantation with the Perfect Pupil expansion device (BD) a very surgeon-friendly procedure, according to E. John Milverton, MD.

New York-Treatment is now available for Fabry's disease, a lysosomal storage disorder with ophthalmologic findings. In April, the FDA granted Orphan Drug designation for agalsidase beta (Fabrazyme, Genzyme General), an enzyme replacement therapy, for the treatment of this progressive and potentially fatal disease.

Cataract surgery in the presence of pseudoexfoliation (PXF) of the lens presents surgeons with unusual challenges. In addition to a higher incidence of glaucoma, these patients have loss of zonular integrity occasionally associated with lens subluxation and pupils that dilate poorly. Although the use of phacoemulsification in experienced hands has resulted in a low incidence of intraoperative and postoperative complications such as zonular dialysis, capsule tears, vitreous loss, and IOL decentration,1 special care should still be exercised when performing cataract surgery in these patients. Improvements in phacoemulsification technology, technique, and capsular supporting rings should ultimately enable these patients to undergo

Birmingham, AL-Glaucoma can arise as a complication of uveitis or as a result of steroids used to treat the inflammatory disorder, said Christopher A. Girkin, MD, associate professor of ophthalmology and director of the glaucoma service, University of Alabama, Birmingham. He reviewed information on the epidemiology, mechanisms, and management of inflammatory and steroid-induced glaucoma.

Chicago-In the late 1980s, ophthalmologists were challenged by Eddy and Billings to prove that IOP was an essential element in the management of primary open-angle glaucoma (POAG). Recent results from a number of National Eye Institute (NEI)-sponsored randomized controlled trials confirm that IOP reduction is effective in slowing both disease development and its progression. The results of those studies, however, have raised new issues in glaucoma management.

Portland, OR-Now, more than ever, people with presbyopia are seeking to put aside their glasses to wear contact lenses. Aging baby boomers prefer to see and be seen without glasses. Career-oriented, they are involved in activities that require good vision not only at near and at distance, but also in the intermediate range.

Measures of success

North Dartmouth, MA-In today's competitive environment, optical dispensaries are under ever-increasing pressure to fill patients' prescriptions not only accurately, but quickly and cost-effectively. It may be time to think about taking the optical end of your practice to the next level, by adding a finishing laboratory, or possibly, even taking a larger jump and setting up a complete surfacing laboratory.

Halifax, Nova Scotia-In a small group of hyperopic patients, laser vision correction (LVC) with multifocal ablations seems to be an advantageous approach for improving both near and distance visual acuity, explained W. Bruce Jackson, MD, FRCSC, during the annual meeting of the Canadian Ophthalmologic Society here.

Washington, DC-The Medicare Coverage Advisory Committee has voted overwhelmingly in favor of making ocular photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis) available as a valid and important treatment for treating AMD in select patients with subfoveal choroidal neovascularization (CNV) with occult but no classic CNV.

Boca Raton, FL-The FDA is granting expedited review status to pre-market approval (PMA) applications it has accepted for the Artisan/Verisyse phakic IOL for the correction of myopia and the endocapsular tension ring.

Atlanta-CIBA Vision Corp. will begin marketing its Centurion SES EpiEdge epikeratome for the Epi-LASIK refractive procedure this fall now that it has obtained U.S. regulatory approval.

Windsor, England-Piggybacking with the low-power meniscus MA60MA IOL (AcrySof, Alcon) is a useful technique for safely and accurately correcting post-cataract surgery ametropia, according to the results of a case series presented by Richard B. Packard, MD.

Visual performance after cataract surgery is superior in eyes with the aspheric IOL implanted compared with other commonly used foldable implants, according to the results of a blinded, prospective, randomized study presented by Robert M. Kershner, MD, FACS.

Exciting progress continues to be made in IOL technology. However, as researchers develop new materials and designs, Nick Mamalis, MD, cautioned that care must to be taken to avoid revisiting old problems so that, as the Barenaked Ladies song title says, "Everything Old is New Again."

Editor's Note: The CrystaLens was recommended for approval by the FDA's Ophthalmic Devices Advisory Panel in late May. The lens may be commercially available later this year or early 2004. Dr. Doane's presentation was given at the annual meeting of the American Society of Cataract and Refractive Surgery prior to the recommendation.

Duluth, GA-Less than a month after Pfizer Inc. announced it would consider selling off the surgical business it acquired with its merger with Pharmacia Corp. (Ophthalmology Times, Sept. 1 issue, Page 3), another large manufacturer of ophthalmic surgical products has announced it is pondering selling the surgical segment of its business as well.